SAN MATEO, Calif. & SHANGHAI--(BUSINESS WIRE)--Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced that Randy Halcomb, Ph.D., senior vice president of chemistry and early development, will present a corporate overview and update on the Company’s lead programs at BioCentury’s 26th Annual Future Leaders in the Biotech Industry Conference on Friday, April 12, 2018 at 2pm Eastern Time in room 404/405. The conference is being held at the Millennium Broadway Hotel in New York City.
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of small molecule drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development, in order to bring promising new therapies to patients in China and other global markets.
For more information, visit www.ternspharma.com and www.ternspharma.com.cn.